Zidesamtinib Tablets 25 mg, 100 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 25 mg, 100 mg

Reference Brands: Jideytro (Nuvalent)

Category: Oncology Cancer Care

Zidesamtinib (Jideytro, Nuvalent) is a ROS1-selective kinase inhibitor for ROS1-positive non-small cell lung cancer after a previous ROS1 inhibitor, approved by the US FDA in July 2026. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.

Product Description:

Zidesamtinib blocks the ROS1 kinase, including the G2032R resistance mutation that stops earlier drugs such as crizotinib and entrectinib from working. It crosses into the brain, where ROS1-positive lung cancer often spreads, and it was designed not to inhibit the related TRK kinases. TRK inhibition causes the dizziness, weight gain and falls seen with some other ROS1 drugs.

The US FDA approved zidesamtinib as Jideytro in July 2026 for adults with ROS1-positive, locally advanced or metastatic non-small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor. It is supplied as 25 mg and 100 mg tablets.

Sourcing and licensing notes. Zidesamtinib is patented and made only by Nuvalent; there is no generic. Other ROS1 options on PharmaTradz include crizotinib, entrectinib, repotrectinib and taletrectinib. We handle enquiries for authorised supply of Jideytro and connect developers and licensees interested in the molecule ahead of patent expiry.